Kimbell Tiger Acquisition Corp (TGR-UN) Peer Comparison
$10.57
As on 08-May-2023 12:00EDT
Market cap
$-- Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
| Kimbell Tiger Acquisition Corp (TGR-UN) | B Riley Principal 250 Merger Corp (BRIV) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|
Market cap ($ Mln) |
-- | 226 | 259 | 65 |
Revenue ($ Mln) |
-- | -- | -- | -- |
Net Profit ($ Mln) |
5.20 | 5.58 | 9.88 | 9.88 |
Net Margin (%) |
-- | 105.83 | 114.93 | 114.93 |
RoE (%) |
2.18 | 3.21 | 4.91 | 4.91 |
Price to Earnings |
-- | 40.74 | -- | 23.00 |
Price-To-Book |
-- | 1.27 | -- | -- |
Income Statement ($ Mln)
| Kimbell Tiger Acquisition Corp (TGR-UN) | B Riley Principal 250 Merger Corp (BRIV) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 0.00 | 0.00 | 0.00 |
|
Cost of Revenue
|
0.00 | 1.75 | 0.00 | 0.00 |
|
Gross Profit
|
-- | -1.18 | -- | -- |
|
Operating Expenses
|
1.81 | 1.13 | 1.30 | 1.30 |
|
Operating Profit (EBIT)
|
-4.47 | -1.13 | -2.36 | -9.90 |
|
Other Income
|
0.00 | 5.28 | 8.59 | 8.59 |
|
Profit before Tax
|
4.24 | 6.40 | 10.73 | 10.73 |
|
Provision for Tax
|
-1.09 | 0.45 | 0.56 | 0.56 |
|
Profit after Tax (Net Income)
|
5.20 | 5.58 | 9.88 | 9.88 |
|
Minority Interest
|
-0.15 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 3.97 | 7.04 | 7.04 |
Liabilities ($ Mln)
| Kimbell Tiger Acquisition Corp (TGR-UN) | B Riley Principal 250 Merger Corp (BRIV) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|
|
Shareholder's Funds
|
233.44 | 174.61 | 202.40 | 202.40 |
|
Minority Interest
|
-0.15 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
237.01 | 0.18 | 10.56 | 10.56 |
|
Current Liabilities
|
9.69 | 0.81 | 1.08 | 1.08 |
|
Total Liabilities
|
241.05 | 175.60 | 214.03 | 214.03 |
Assets ($ Mln)
| Kimbell Tiger Acquisition Corp (TGR-UN) | B Riley Principal 250 Merger Corp (BRIV) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|
|
Non-Current Assets
|
0.00 | 174.44 | 213.85 | 213.85 |
|
Current Assets
|
243.24 | 1.16 | 0.19 | 0.19 |
|
Total Assets
|
241.05 | 175.60 | 214.03 | 214.03 |
|
Total Debt*
|
0.00 | 0.00 | 0.00 | 0.00 |
|
Net Current Assets
|
233.55 | 0.00 | 0.00 | 0.00 |
Cashflow ($ Mln)
| Kimbell Tiger Acquisition Corp (TGR-UN) | B Riley Principal 250 Merger Corp (BRIV) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|
|
Cash From Operating Activities
|
-1.76 | -0.61 | -0.87 | -0.87 |
|
Cash Flow from Investing Activities
|
-- | -- | 0.34 | 0.34 |
|
Cash from Financing Activities
|
239.02 | 0.00 | -0.01 | -0.01 |
|
Net Cash Inflow / Outflow
|
-- | -0.61 | -0.54 | -0.54 |
Ratios
Profitability Ratios
| Kimbell Tiger Acquisition Corp (TGR-UN) | B Riley Principal 250 Merger Corp (BRIV) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|
|
ROCE (%)
|
1.00 | 3.16 | 5.80 | 5.80 |
|
ROE (%)
|
2.18 | 3.21 | 4.91 | 4.91 |
|
ROA (%)
|
2.10 | 3.18 | 4.63 | 4.63 |
|
EBIT Margin (%)
|
-- | -- | -- | -- |
|
Net Margin (%)
|
-- | 105.83 | 114.93 | 114.93 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- |
Growth Ratios
| Kimbell Tiger Acquisition Corp (TGR-UN) | B Riley Principal 250 Merger Corp (BRIV) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | -- | -- | -- |
|
EBIT Growth (%)
|
-- | -344.60 | -- | 1,391.00 |
|
Net Profit Growth (%)
|
409.41 | 90.91 | -- | -100.00 |
|
EPS Growth (%)
|
4.09 | 4.99 | -- | -- |
|
Book Value Growth (%)
|
-42.53 | -- | 5,221.48 | -- |
Valuation Ratios
| Kimbell Tiger Acquisition Corp (TGR-UN) | B Riley Principal 250 Merger Corp (BRIV) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|
|
Price / Earnings
|
116.04 | 7.32 | 23.25 | -- |
|
Price / Book Value
|
0.58 | 0.23 | 1.31 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- |
|
EV/EBITDA
|
98.03 | -6.83 | -- | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- |
Solvency Ratios
| Kimbell Tiger Acquisition Corp (TGR-UN) | B Riley Principal 250 Merger Corp (BRIV) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.00 | 0.00 | 0.00 | 0.00 |
|
Current Ratio
|
25.11 | 1.43 | 0.17 | 0.17 |
|
Quick Ratio
|
25.11 | 1.43 | 0.17 | 0.17 |
|
Interest Coverage
|
1.60 | 2.21 | 2.11 | 1.62 |
Operating Efficiency Ratios
| Kimbell Tiger Acquisition Corp (TGR-UN) | B Riley Principal 250 Merger Corp (BRIV) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | -- | -- | -- |
|
Asset Turnover
|
0.00 | 0.00 | 0.00 | 0.00 |
|
Receivable days
|
-- | -- | -- | -- |
|
Inventory Days
|
-- | -- | -- | -- |
|
Payable days
|
-- | 71.34 | -- | -- |
|
Cash Conversion Cycle
|
-- | -- | -- | -- |